Articles by tag: survodutide

Survodutide trials: failure or effectiveness in weight loss?

Phase 3 SYNCHRONIZE-1 analysis: weight loss 13-16.6%, but 19% discontinuations due to side effects. Is it worth the risk? Read the full review.

Survodutide in obesity: 13% efficacy in phase 3

The new dual agonist Survodutide showed 13% weight reduction in patients with obesity without diabetes. Learn about the mechanism of action, side effects, and prospects of the drug.